References
Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27
Lange U, Teichmann J, Obermayer-Pietsch B (2009) Genetic aspects of osteopenia/osteoporosis in ankylosing spondylitis. Z Orthop Unfall 147:577–581
Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48:535–538
Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349
Lange U, Teichmann J, Müller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology 44:1546–1548
Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I (1997) Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99:1699–1703
Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS et al (2012) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 71(Suppl II):i2–i45
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368
Lange U, Boss B, Teichmann J, Stracke H, Neeck G (2000) Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica—a prospective study on the influence of glucocorticoid therapy. Z Rheumatol 59(Suppl 2):II/137–II/141
Star VL, Hochberg MC (1994) Osteoporosis in patients with rheumatic diseases. Rheum Dis Clin N Am 20:561–576
Oelzner P, Muller A, Deschner F, Hüller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193–198
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499
Eekman DA, Vis M, Bultink IEM, Kuik DJ, Voskuyl AE, Dijkmans BAC, Lems WF (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:389–390
Kimble RB, Bain S, Pacifici R (1997) The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12:935–941
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124
Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C (2007) Miossec P (2007) A 1-year case–control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Gabriel Dischereit and Ingo H. Tarner contributed equally to this study.
Rights and permissions
About this article
Cite this article
Dischereit, G., Tarner, I.H., Müller-Ladner, U. et al. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 32, 377–381 (2013). https://doi.org/10.1007/s10067-012-2128-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2128-8